Actavis to spend $66 billion on Allergan
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
Nov 17, 2014
0
0
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
Nov 17, 2014
0
0
AmSurg says it will spend about $2.35 billion to buy Sheridan Healthcare in a cash and stock deal that adds physician outsourcing services to the ambulatory surgery center operator's portfolio.
May 29, 2014
0
0
An hour's drive south of Canada's capital, past snow-covered pine forests and farmland, Chuck Rifici is growing marijuana at an old Hershey's factory.
Feb 16, 2014
0
0
Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.
Feb 5, 2014
0
0
Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, slid 19 percent Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing plant of the firm.
Jan 24, 2014
0
0
US generic drug specialist Mylan said Thursday it had completed its $1.75 billion acquisition of a unit of India's Strides Arcolab, boosting its presence in the high-growth injectable drugs market.
Dec 5, 2013
0
0
Forest Laboratories says it plans to cut $500 million in costs in about two years, and also plans to buy back up to $1 billion in company stock.
Dec 2, 2013
0
0
The US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products, sending the company's shares tumbling 14 percent on Wednesday.
Nov 27, 2013
0
0
Shares of the Indian units of US pharmaceutical firms Pfizer and Wyeth soared Monday, after the pair approved a merger plan which would create India's ninth largest drug company.
Nov 25, 2013
0
0
The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.
Nov 11, 2013
0
0